Answers are grounded in this paper and cite their sources.
Among persons with both chronic kidney disease and type 2 diabetes, initial therapy with finerenone plus empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either treatment alone. (Funded by Bayer; CONFIDENCE ClinicalTrials.gov number, NCT05254002.).
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: